All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

EMA Validates Filings for Denosumab Biosimilar Candidate HLX14 for Osteoporosis

May 24th 2024

Marketing authorization applications for the denosumab biosimilar HLX14 have been validated by the EMA.

AI Support Tool Demonstrates Detection Utility for Melanoma at Primary Care Practices

May 24th 2024

An artificial intelligence-based smartphone app used by primary care physicians showed high diagnostic accuracy in detecting cutaneous melanoma.

Vanderbilt Symposium Highlights Recent Data on Novel Agents Under Evaluation in Hematologic Malignancies

May 24th 2024

Katie S. Gatwood, PharmD, BCOP, explains next steps with novel agents in the hematologic oncology field that have the potential to change practice.

Prospective Data Reveal Most Young Survivors of Breast Cancer Could Successfully Give Birth

May 23rd 2024

Most women who attempted to conceive following treatment for stage I to III breast cancer were able to become pregnant at least once.

HPV Vaccinations Associated With Lower Rates of HPV-Caused Cancers in Patients Under 40 Years of Age

May 23rd 2024

Patients under the age of 40 who received HPV vaccines were associated with lower rates of HPV-related cancer vs unvaccinated patients.

AI Virtual Navigation May Reengage Patients to Undergo Missed Colonoscopies

May 23rd 2024

An artificial intelligence-based navigation tool may be used to call patients who previously missed their colonoscopy appointment with the goal that they will reschedule and attend the new appointment.

Long-Term Findings Clarify Role of Estrogen Therapy on Ovarian/Endometrial Cancer Incidence

May 23rd 2024

Treatment with CEE alone was associated with increased ovarian cancer incidence and mortality rates in postmenopausal women who had undergone hysterectomy.

Narayan Discusses Bladder Preservation and the Role of Gene Therapies in NMIBC

May 23rd 2024

Vikram M. Narayan, MD, highlights takeaways from 5-year follow-up data examining the gene therapy nadofaragene firadenovec and details promising emerging therapies for bladder cancer.

Roswell Park Again Named an ‘LGBTQ+ Healthcare Equality Leader’

May 23rd 2024

Roswell Park Comprehensive Cancer Center earned top score of 100 on Human Rights Campaign Foundation survey.

FDA Grants Fast Track Designation to VCN-01 in Metastatic Pancreatic Cancer

May 23rd 2024

VCN-01 plus gemcitabine and nab-paclitaxel has received fast track designation from the FDA in metastatic pancreatic adenocarcinoma.

Exploiting the Vulnerabilities of High-Grade Serous Ovarian Cancer Through WEE1 Inhibition

May 23rd 2024

Joyce F. Liu, MD, MPH, provides insights on WEE1 which has emerged as a potentially targetable pathway in high-grade serous ovarian cancer.

Advances With Erdafitinib Exemplify the Push For Precision Medicine in Urothelial Cancer

May 23rd 2024

Petros Grivas, MD, PhD, expands on key updates in the second-line management of urothelial cancer.

Exploring Vaccine Approaches for Immunoprevention in Low-Grade Glioma

May 22nd 2024

Hideho Okada, MD, PhD, discusses cancer immunoprevention through the lens of vaccine approaches in patients with low-grade glioma.

Cancer Vaccines Approach New Horizons in Melanoma and Other Solid Tumors

May 22nd 2024

Patrick Ott, MD, PhD, discusses the investigation of cancer vaccines, highlighting the clinical implications of this treatment modality in melanoma.

JAK Inhibitor–Based Combinations Could Represent the Next Frontier in Myelofibrosis

May 22nd 2024

Ashwin Kishtagari, MD, discusses the investigation of JAK inhibitor–based combinations in myelofibrosis.

Expansion of Frontline Immunotherapy Regimens Improves Prognosis, Increases Optimism in Urothelial Cancer

May 22nd 2024

Peter H. O’Donnell, MD, provides insights on key developments in bladder cancer management and how they have generated optimism within the field.

Fox Chase Researcher Mitchell Fane Awarded $255,000 Grant to Explore Relationship Between Aging and Melanoma

May 22nd 2024

Mitchell Fane, PhD, has received a grant to investigate the role of aging in immune-regulated reactivation from metastatic melanoma.

Guardant360 CDx Gains European Union Certification for Tumor Profiling in Solid Tumors

May 22nd 2024

Guardant360 CDx received In Vitro Diagnostic Regulation certification for tumor mutation profiling in solid tumors and for companion diagnostic indications in NSCLC and breast cancer.

European Commission Approves Two Denosumab Biosimilars

May 22nd 2024

Two biosimilars for reference denosumab have received marketing authorization from the European Commission.

Eckfeldt Looks Towards the Future of AML and MDS Care

May 22nd 2024

Craig Eckfeldt, MD, PhD, discusses key updates in the MDS treatment paradigm and the implications of MRD testing, as well as next steps in the field of AML.